Silverback Therapeutics Stock In The News
| SPRY Stock | 13.48 0.91 7.24% |
Our overall analysis of Silverback Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Silverback Therapeutics. The specific impact of Silverback Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Silverback Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Silverback Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Silverback Therapeutics Backtesting and Silverback Therapeutics Hype Analysis. For more information on how to buy Silverback Stock please use our How to Invest in Silverback Therapeutics guide.
Silverback |
Silverback Therapeutics Today Top News and Investor Outlook
Silverback Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Silverback and other traded companies coverage with news coverage. We help investors stay connected with Silverback headlines for the 21st of January to make an informed investment decision based on correlating the impacts of news items on Silverback Stock performance. Please note that trading solely based on the Silverback Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Silverback Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Silverback earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Silverback Therapeutics that are available to investors today. That information is available publicly through Silverback media outlets and privately through word of mouth or via Silverback internal channels. However, regardless of the origin, that massive amount of Silverback data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Silverback Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Silverback Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Silverback Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Silverback Therapeutics alpha.
Silverback Largest EPS Surprises
Earnings surprises can significantly impact Silverback Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-09 | 2023-09-30 | -0.18 | -0.16 | 0.02 | 11 | ||
2024-11-07 | 2024-09-30 | -0.15 | -0.2 | -0.05 | 33 | ||
2024-03-21 | 2023-12-31 | -0.14 | -0.07 | 0.07 | 50 | ||
2022-08-11 | 2022-06-30 | -0.48 | -0.55 | -0.07 | 14 | ||
2022-11-02 | 2022-09-30 | -0.35 | -0.5 | -0.15 | 42 | ||
2022-05-12 | 2022-03-31 | -0.54 | -0.7 | -0.16 | 29 |
Silverback Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Silverback Therapeutics Stock. Current markets are slightly bullish. About 55% of major world exchanges and indexes are currently up. See today's market update for more information.
13th of January 2025
ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 O... at finance.yahoo.com
8th of January 2025
Insider Sell Laura Shawver Sells 50,000 Shares of ARS Pharmaceuticals Inc at gurufocus.com
6th of January 2025
ARS Pharmaceuticals Files for Approval of neffy in Canada and t at gurufocus.com
2nd of January 2025
Acquisition by Eric Karas of 152300 shares of Silverback Therapeutics at 10.71 subject to ... at MacroaxisInsider
19th of December 2024
ARS Pharmaceuticals Announces neffy is available on Express Scripts Commercial National Fo... at finance.yahoo.com
16th of December 2024
Insider Selling ARS Pharmaceuticals, Inc. COO Sells 25,000 Shares of Stock at thelincolnianonline.com
13th of December 2024
ARS neffy at globenewswire.com
12th of December 2024
Disposition of 25000 shares by Dorsey Brian of Silverback Therapeutics at 12.2973 subject ... at gurufocus.com
11th of December 2024
Disposition of 15000 shares by Dorsey Brian of Silverback Therapeutics at 12.4284 subject ... at MacroaxisInsider
4th of December 2024
ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Sav... at gurufocus.com
14th of November 2024
ARS Pharmaceuticals Stock Price Up 6 percent Heres Why at thelincolnianonline.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Silverback Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Silverback Therapeutics' short interest history, or implied volatility extrapolated from Silverback Therapeutics options trading.
Additional Tools for Silverback Stock Analysis
When running Silverback Therapeutics' price analysis, check to measure Silverback Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Silverback Therapeutics is operating at the current time. Most of Silverback Therapeutics' value examination focuses on studying past and present price action to predict the probability of Silverback Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Silverback Therapeutics' price. Additionally, you may evaluate how the addition of Silverback Therapeutics to your portfolios can decrease your overall portfolio volatility.